A to Z of antiretroviral drugs

Prior to using a new medication, there are certain issues that should be discussed before the first dose is taken. This should include a clear understanding of the following:

  • The reasons for selecting a particular treatment regimen.
  • A drug/regimen's past efficacy and expected treatment outcomes.
  • All dosing issues, including how a medication is taken, how often, how much, and when.
  • Likely and/or potential treatment side-effects.
  • An awareness of the difference between an 'expected' reaction and a severe adverse reaction that merits checking in with the clinic.
  • Possible interactions with other drugs the person is already taking.

Knowing in advance that a drug often causes a certain reaction (for instance, headache, rash, or stomach pain) to some extent prepares someone to handle the problem. Generally, the fewer surprises involved, the better it is for everyone involved.

  • 3TC (lamivudine, Epivir)

    Information on 3TC (lamivudine, Epivir), including dosing, effectiveness, side-effects, resistance and drug interactions.

  • Abacavir (Ziagen)

    Abacavir is an anti-HIV drug that reduces the amount of virus in the body. Anti-HIV drugs such as abacavir slow down or prevent damage to

  • Atazanavir (Reyataz)

    Information on the protease inhibitor atazanavir (Reyataz), including its effectiveness, side-effects and drug interactions.

  • Atripla

    Atripla is a fixed-dose tablet combining 600mg efavirenz, 200mg FTC (emtricitabine), and 245mg tenofovir, manufactured jointly by Bristol-Myers Squibb and Gilead Sciences. Efavirenz is a non-nucleoside reverse

  • AZT (zidovudine, Retrovir)

    Information on AZT (zidovudine, Retrovir), including its effectiveness, side-effects, drug interactions and use in pregnant women and children.

  • Combivir (AZT/3TC)

    Combivir is a fixed-dose combination tablet comprising 150mg 3TC (lamivudine) and 300mg AZT (zidovudine) manufactured by GlaxoSmithKline. AZT and 3TC are both nucleoside reverse transcriptase

  • d4T (stavudine, Zerit)

    d4T (stavudine, Zerit) is an anti-HIV drug that reduces the amount of virus in the body. Anti-HIV drugs such as d4T slow down or prevent

  • Darunavir (Prezista)

    Information on the protease inhibitor darunavir.

  • ddI (didanosine, Videx/VidexEC)

    ddI (didanosine, Videx/VidexEC) is an anti-HIV drug that reduces the amount of virus in the body. Anti-HIV drugs such as ddI slow down or prevent

  • Delavirdine (Rescriptor)

    Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). The enzyme reverse transcriptase converts single-stranded viral RNA into DNA. Drugs in the non-nucleoside reverse transcriptase inhibitor

  • Dolutegravir (Tivicay)

    Dolutegravir (Tivicay) belongs to the class of antiretroviral drugs known as integrase inhibitors. The drug works against HIV's integrase protein, blocking its ability to integrate its genetic code

  • Efavirenz (Sustiva)

    Efavirenz (Sustiva) is an anti-HIV drug that reduces the amount of virus in the body. Anti-HIV drugs such as efavirenz slow down damage to the

  • Elvitegravir (Vitekta)

    Elvitegravir (Vitekta) belongs to the class of antiretroviral drugs known as integrase inhibitors. The drug works against HIV's integrase protein, blocking its ability to integrate its genetic code

  • Enfuvirtide (T-20, Fuzeon)

    Information on T-20 (Fuzeon), including effectiveness, side-effects, resistance and its use in children and pregnant women.

  • Etravirine (Intelence)

    Etravirine (Intelence) is an anti-HIV drug that reduces the amount of virus in the body and belongs to the class of drugs known as non-nucleoside reverse transcriptase

  • Eviplera

    Eviplera is a fixed-dose tablet combining 25mg rilpivirine, 200mg FTC (emtricitabine), and 245mg tenofovir, manufactured jointly by Johnson & Johnson/Tibotec and Gilead Sciences. Rilpivirine is a non-nucleoside

  • Fosamprenavir (Telzir, Lexiva)

    Fosamprenavir (Telzir) is an anti-HIV drug that reduces the amount of virus in the body. Anti-HIV drugs such as fosamprenavir slow down or prevent damage

  • FTC (emtricitabine, Emtriva)

    FTC (emtricitabine, Emtriva) is an antiviral drug that reduces the amount of HIV in the body. Anti-HIV drugs such as FTC slow down or prevent

  • Indinavir (Crixivan)

    Indinavir (Crixivan) is an anti-HIV drug that reduces the amount of virus in the body. Anti-HIV drugs such as indinavir slow down or prevent damage

  • Kivexa (abacavir/3TC)

    Kivexa (Epzicom) is a fixed-dose combination tablet combining 300mg 3TC (lamivudine) and 600mg abacavir, manufactured by GlaxoSmithKline. Abacavir and 3TC are both nucleoside reverse transcriptase inhibitors (NRTIs). The standard

  • Lopinavir/ritonavir (Kaletra)

    Lopinavir/ritonavir (Kaletra, Aluvia) is a protease inhibitor drug available in tablet and solution form. Lopinavir is marketed only with a boosting dose of ritonavir; ritonavir is marketed separately as Norvir.

  • Maraviroc (Celsentri)

    Maraviroc (known by the trade name Celsentri in Europe and Selzentry in the United States) is the first drug to be licensed from a new class

  • Nelfinavir (Viracept)

    Nelfinavir is a protease inhibitor, an anti-HIV drug that reduces the amount of virus in the body. Anti-HIV drugs such as nelfinavir slow down or prevent

  • Nevirapine (Viramune)

    Nevirapine (Viramune) is an anti-HIV drug that reduces the amount of virus in the body. Anti-HIV drugs such as nevirapine slow down damage to the immune

  • Raltegravir (Isentress)

    Raltegravir (Isentress) is an HIV-1 integrase strand-transfer inhibitor with potent antiretroviral activity. It belongs to a new class of antiretrovirals called integrase inhibitors. The drug works

  • Rilpivirine (Edurant)

    Rilpivirine (Edurant), previously known as TMC278) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), developed by Johnson & Johnson/Tibotec. Rilpivirine was submitted for licensing in

  • Ritonavir (Norvir)

    Ritonavir (Norvir) is a protease inhibitor, an anti-HIV drug that reduces the amount of virus in the body. Anti-HIV drugs such as ritonavir slow down or prevent

  • Saquinavir (Invirase)

    Information on saquinavir (Invirase / Fortovase), including efficacy, boosting with ritonavir (Norvir), side-effects, resistance, drug interactions and the treatment of children and pregnant women.

  • Stribild

    Stribild is a fixed-dose tablet combining 150mg elvitegravir, 200mg emtricitabine, and 245mg tenofovir disoproxil, along with 150mg cobicistat, a boosting agent. It is manufactured by Gilead

  • Tenofovir (Viread)

    Tenofovir (Viread) is an antiviral drug that is approved for the treatment of HIV infection. It is able to reduce the amount of HIV in

  • Tipranavir (Aptivus)

    Information on tipranavir (Aptivus), including dosing, availability, effectiveness and drug resistance.

  • Triomune

    Triomune is a co-formulation of three drugs commonly used in the management of HIV infection. It contains generic versions of the nucleoside reverse transcriptase inhibitors lamivudine (3TC) and

  • Trizivir (AZT/3TC/abacavir)

    Trizivir is a fixed-dose combination tablet containing 150mg 3TC (lamivudine, Epivir), 300mg abacavir and 300mg AZT (zidovudine, Retrovir). It is manufactured by GlaxoSmithKline. 3TC, abacavir and AZT are

  • Truvada (tenofovir/FTC)

    Truvada is a fixed-dose combination tablet combining 200mg FTC (emtricitabine) and 245mg tenofovir. It is manufactured by Gilead Sciences. FTC is a nucleoside reverse transcriptase inhibitor (NRTI)

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close